COMPARE · Reviewed July 29, 2026
ANIP vs ZTS
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 84.2, ZTS scored 78.0 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
84.2
$81.78 · $1.9B
fundamentals as of
Score gap
6.2
ANIP leads
ZTS
Zoetis Inc.
78
$77.93
fundamentals as of
Fundamentals, head-to-head
ANIP
ZTS
$191mC
FCF
$2.2bB
+37.0%A
Rev
+2.6%C
1.12C
D/E
2.86D
20.9xB+
P/E
12.8xA
0.48A
PEG
1.84C+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
ZTS
48% below
Price vs fair valuelower is cheaper
—
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+68%
1-yr DCF upside
—
+94%
5-yr DCF upside
—
+138%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.9b. 18% off the 52-week high of $99.50. Revenue growing +37% — in hypergrowth territory. PEG 0.48 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $110.00 (implying +35% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ZTSZoetis Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap n/a. Down 51% from 52-week high of $160.48 — deep drawdown territory. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $111.94 (implying +44% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 82% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.86 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.